CCO Expert Recap

Investigational Antiretrovirals

Source: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention

Update on Investigational Antiretrovirals

Faculty:

Joseph J. Eron, Jr., MD
  • Joseph J. Eron, Jr., MD

CME CREDIT INFORMATION

Release Date: 09/28/07

Expiration Date: 09/27/08


Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.8 Nursing CE credits

Status: Please log in to view status
Begin the CCO Expert Recap

Joseph J. Eron, Jr., MD, discusses the most clinically relevant data on investigational antiretroviral agents from the 2007 International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the results of recent clinical studies of the CCR5 antagonists maraviroc and vicriviroc in treatment-naive and treatment-experienced HIV-infected patients
  • Summarize the safety and efficacy of the investigational integrase inhibitor raltegravir in treatment-naive HIV-infected patients
  • Recount recent findings from studies of the investigational NNRTIs rilpivirine and etravirine in treatment-naive and treatment-experienced HIV-infected patients

Slideset

Update on Investigational Antiretrovirals


Joseph J. Eron, Jr., MD, discusses the most clinically relevant data on investigational antiretrovirals from the 2007 IAS International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention.


Format: Microsoft PowerPoint (.ppt) | File size: 943 KB